All GLP-1 medications from licensed 503A compounding pharmacies Browse Products

Medicare TRT Coverage 2026

Medicare covers TRT only for medically diagnosed hypogonadism with symptoms. Learn coverage requirements, costs, and alternatives for 2026.

By Dr. Marcus Rivera, MD, Endocrinology|Reviewed by Dr. David Kim, MD, FACE||

Medically Reviewed

Written by Dr. Marcus Rivera, MD, Endocrinology · Reviewed by Dr. David Kim, MD, FACE

Medicare TRT Coverage 2026 custom 2026 header image for Cost Guides
Custom header image for Medicare TRT Coverage 2026, Cost Guides, and better treatment decision-making.
In This Article

This article is part of our Cost Guides collection. See also: Provider Comparisons | GLP-1 Guides

Search and AI answer brief

Practical answer: Medicare TRT Coverage 2026

Medicare covers TRT only for medically diagnosed hypogonadism with symptoms. Learn coverage requirements, costs, and alternatives for 2026.

Short answer

Medicare covers TRT only for medically diagnosed hypogonadism with symptoms. Learn coverage requirements, costs, and alternatives for 2026.

Search intent

This page answers a specific Cost Guides question rather than a generic overview.

What to verify

semaglutide, tirzepatide, hormone labs and monitoring, peptide evidence quality

How to use it

Use this information to prepare sharper questions for a licensed provider.

Medicare covers testosterone replacement therapy only for medically diagnosed hypogonadism with documented symptoms and low testosterone levels below 300 ng/dL on two separate tests. Coverage requires prior authorization and typically covers 80% of costs after the Part B deductible of $240 in 2026. Medicare Part D may cover testosterone gels and patches with copays ranging from $30-150 per month depending on your plan. Injectable testosterone cypionate through Medicare Part B averages $45-80 per injection when administered in a clinical setting. Medicare Advantage plans often provide enhanced coverage with lower copays, sometimes reducing monthly costs to $15-40. However, Medicare excludes coverage for testosterone therapy prescribed solely for age-related decline, wellness purposes, or muscle building without documented hypogonadism symptoms.

See your GLP-1 options in about 2 minutes. Free and private. See my options →
  • Medicare requires documented hypogonadism diagnosis with testosterone levels below 300 ng/dL
  • Coverage includes 80% of approved treatments after meeting the $240 Part B deductible
  • Prior authorization is mandatory for all testosterone replacement therapies
  • Injectable testosterone through Part B costs $45-80 per injection in clinical settings
  • Alternative therapies like peptide therapy may require out-of-pocket payment

Medicare Coverage Requirements for Testosterone Replacement Therapy

Medicare establishes strict medical criteria for testosterone replacement therapy coverage that extends beyond simple low testosterone readings. Your healthcare provider must document primary or secondary hypogonadism through full testing, including two separate morning testosterone measurements below 300 ng/dL taken at least one week apart. The Centers for Medicare & Medicaid Services requires evidence of hypogonadal symptoms such as decreased libido, erectile dysfunction, fatigue, or mood changes that correlate with laboratory findings. Prior authorization becomes mandatory for all testosterone formulations under Medicare coverage. Your doctor must submit documentation proving medical necessity, including symptom assessments, physical examination findings, and laboratory results. Medicare reviews each case individually, and approval typically takes 5-10 business days. Patients with testosterone levels between 300-400 ng/dL may face additional scrutiny and require more extensive documentation to justify treatment necessity.

Medicare Part B and Part D Coverage Differences

Medicare Part B covers injectable testosterone cypionate and enanthate when administered in approved clinical settings, treating these as medical procedures rather than prescription medications. After meeting your annual deductible of $240, Medicare pays 80% of the Medicare-approved amount, leaving you responsible for the remaining 20% plus any provider charges above Medicare's approved rates. Monthly injection costs typically range from $45-80 per treatment session. Medicare Part D handles testosterone gels, patches, and other self-administered formulations as prescription drugs. Coverage varies significantly between Part D plans, with formulary placement affecting your out-of-pocket costs. Testosterone gels like AndroGel or Testim may require step therapy, where you must try less expensive alternatives first. Monthly copays range from $30-150 depending on your specific Part D plan and whether the medication falls into a preferred or non-preferred tier.

Medicare Advantage and Supplemental Coverage Options

Medicare Advantage plans often provide enhanced testosterone replacement therapy coverage compared to Original Medicare, with some plans offering $15-40 monthly copays for preferred testosterone formulations. These plans may also cover additional hormone-related services like specialized endocrinology consultations or enhanced laboratory monitoring that Original Medicare limits. Medigap policies help cover the 20% coinsurance gap for Part B-covered testosterone injections, potentially reducing your out-of-pocket expenses to zero for approved treatments. However, Medigap plans cannot enhance Part D prescription drug coverage for self-administered testosterone preparations. Consider exploring Sermorelin or other growth hormone-releasing peptides as alternative approaches, though these typically require private pay arrangements.

Frequently Asked Questions

Medicare does not cover testosterone replacement therapy for age-related testosterone decline or "andropause" without documented hypogonadism. You must have testosterone levels below 300 ng/dL with corresponding symptoms and a medical diagnosis of primary or secondary hypogonadism. Wellness-focused testosterone therapy requires private payment, typically costing $200-400 monthly for thorough treatment programs.

See transparent compounded pricing

Review compounded medication pricing and what provider-reviewed care includes, with no surprises at checkout.

Try the Cost Calculator →
Monthly GLP-1 Medication Cost Comparison Relative Cost Index 0 23 47 71 95 95 90 88 25 Brand Ozempic Brand Wegovy Brand Mounjaro Compounded Average retail pricing as of 2026
Monthly GLP-1 Medication Cost Comparison. Average retail pricing as of 2026.
View data table
Bar chart showing monthly glp-1 medication cost comparison: Brand Ozempic (95), Brand Wegovy (90), Brand Mounjaro (88), Compounded (25)
CategoryRelative Cost IndexDetail
Brand Ozempic95$900-1,350/mo without insurance
Brand Wegovy90$1,300-1,600/mo without insurance
Brand Mounjaro88$1,000-1,200/mo without insurance
Compounded25$299-449/mo at FormBlends

What documentation does Medicare require for TRT approval?

Medicare requires two separate morning testosterone measurements below 300 ng/dL, detailed symptom documentation, physical examination findings consistent with hypogonadism, and medical history ruling out reversible causes of low testosterone. Your provider must also document failed or inappropriate alternative treatments and provide detailed treatment plans with monitoring protocols for prior authorization approval.

Are there Medicare-covered alternatives to traditional testosterone therapy?

Medicare may cover clomiphene citrate for younger men with secondary hypogonadism, as this medication can stimulate natural testosterone production. Human chorionic gonadotropin (hCG) injections receive limited coverage for specific hypogonadal conditions. However, newer treatments like BPC-157 or TB-500 peptides remain experimental and require private payment arrangements.

How much will I pay out-of-pocket for Medicare-covered TRT?

After meeting the $240 Part B deductible, you'll pay 20% of Medicare-approved amounts for injectable testosterone, typically $10-20 per injection. Part D prescription copays vary by plan but average $30-80 monthly for testosterone gels or patches. Medicare Advantage plans may reduce these costs to $15-40 monthly, while Medigap policies can eliminate Part B coinsurance entirely.

Can Medicare deny coverage for medically necessary testosterone therapy?

Medicare can deny coverage if documentation doesn't meet medical necessity criteria, testosterone levels exceed 300 ng/dL, or symptoms don't correlate with hypogonadal diagnosis. Denials often occur when providers fail to rule out reversible causes like medications, obesity, or sleep disorders. You can appeal Medicare decisions through a formal review process that typically takes 30-60 days for resolution.

Sources

  1. Centers for Medicare & Medicaid Services. Medicare Coverage Guidelines for Testosterone Replacement Therapy. CMS Manual Publication 100-03, Section 210.2. Updated January 2026.
  2. Bhasin S, et al. Testosterone therapy in men with hypogonadism: an Endocrine Society clinical practice guideline. Journal of Clinical Endocrinology & Metabolism. 2018;103(5):1715-1744. PMID: 29562364.
  3. Medicare Part D Prescription Drug Coverage Analysis. 2026 Formulary Review of Testosterone Preparations. Medicare.gov Resource Center. March 2026.
  4. Mulhall JP, et al. Evaluation and management of testosterone deficiency: AUA guideline. Journal of Urology. 2018;200(2):423-432. PMID: 29601923.
  5. Medicare Advantage Plan Performance Data. Hormone Replacement Therapy Coverage Analysis 2024-2026. Centers for Medicare & Medicaid Services Statistical Report.
  6. Corona G, et al. Hypogonadism as a risk factor for cardiovascular mortality in men: a meta-analytic study. European Journal of Endocrinology. 2011;165(5):687-701. PMID: 21852391.
  7. Medicare Appeals Process for Hormone Therapy Denials. Administrative Law Judge Decision Database 2025-2026. Social Security Administration Healthcare Appeals Division.

See your options in about 2 minutes

Take the free quiz and see what fits you. Quick, private, and no commitment to continue.

See my options →

Evidence standard

How this page was source-checked

Editorial policy

FormBlends does not claim an individual clinician byline unless a named reviewer is available. For this page, the editorial team checks medical and regulatory claims against primary sources, clinical trials, public datasets, and regulator guidance.

PubMed evidence trail

Research sources used to frame this page

For Medicare TRT Coverage 2026, FormBlends checks the page topic against primary trials, systematic reviews, guidelines, and current PubMed-indexed literature where available. These citations are context, not medical advice, proof of eligibility, or a claim that every study applies to every patient.

Randomized trialTestosterone and TRT evidence2023

Cardiovascular Safety of Testosterone-Replacement Therapy

TRAVERSE trial anchor for cardiovascular-safety discussions in appropriately diagnosed men.

PubMed

GuidelineTestosterone and TRT evidence2010

Testosterone therapy in men with androgen deficiency syndromes: an Endocrine Society clinical practice guideline

Guideline anchor for diagnosis, monitoring, contraindications, and appropriate TRT framing.

PubMed

ReviewTestosterone and TRT evidence2026

Functional testosterone deficiency in aging men: Clinical impact, diagnostic pathways, and treatment strategies

Current review context for aging men, diagnosis pathways, and treatment caution.

PubMed

ReviewNAD+ and precursor evidence2021

NAD+ metabolism and its roles in cellular processes during ageing

Core review for NAD+ decline, mitochondrial function, DNA repair, and aging biology.

PubMed

Randomized trialNAD+ and precursor evidence2021

Nicotinamide mononucleotide increases muscle insulin sensitivity in prediabetic women

Human NMN source for metabolic claims while keeping population limits clear.

PubMed

Randomized trialNAD+ and precursor evidence2018

Chronic nicotinamide riboside supplementation is well-tolerated and elevates NAD+ in healthy middle-aged and older adults

Human NR source for NAD+ level and tolerability discussions.

PubMed

ReviewMenopause and hormone evidence2012

Understanding weight gain at menopause

Background source for body-composition and weight-change discussions around menopause.

PubMed

ReviewMenopause and hormone evidence2024

Management of obesity in menopause

Current source for menopause-specific obesity management framing.

PubMed

ReviewMenopause and hormone evidence2022

Management of menopause: a view towards prevention

Used for broad prevention and risk-benefit context in hormone-related pages.

PubMed

Hormone decision path

Use the page to prepare for a monitored care conversation

Direct answer

Medicare TRT Coverage 2026 is a clinical decision, not a generic supplement choice. Symptoms, labs, history, medication use, fertility goals, and follow-up monitoring all matter.

Evidence check

The best next read should connect symptoms and outcomes to labs, safety monitoring, and real provider decision points.

Safety check

Hormone therapy requires licensed review because dosing, contraindications, fertility, mood, cardiovascular risk, and follow-up labs can change the plan.

Next step

Continue into the get-started flow when you want a provider to evaluate whether this path fits your situation.

Original tools and data

Use the FormBlends research stack

These assets are built to be useful beyond a single article: shareable data pages, calculators, provider comparisons, and safety checks that give Google and readers something original to crawl.

Editorial refresh

Practical 2026 note for Medicare TRT Coverage 2026

For this cost guides page, the 2026 refresh focuses on BPC-157, testosterone, cash-pay pricing, trt, covered, medicare so the article stays close to the question behind "Medicare TRT Coverage 2026".

The useful details are the practical ones: what to verify, what changes risk or cost, and which details separate Medicare TRT Coverage 2026 from nearby GLP-1, peptide, hormone, or provider-comparison searches.

Readers can use the added context to bring sharper questions to a licensed provider before making a treatment, cost, or care decision.

Medicare TRT Coverage 2026 custom 2026 image for cost guides on FormBlends

Custom 2026 image for Medicare TRT Coverage 2026, cost guides, and better treatment decision-making.

Image description: Unique image for this page covering Medicare TRT Coverage 2026, cost guides, safety, cost, provider selection, and patient decision-making.

Download the Cost Comparison Worksheet

A printable worksheet to compare brand vs. compounded pricing for GLP-1 medications and peptides.

Free download. We'll also send helpful GLP-1 guides to your inbox. Unsubscribe anytime.

Medical Disclaimer: This content is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare provider before starting, stopping, or changing any medication or treatment. FormBlends articles are source-checked against medical and regulatory references, but they are not a substitute for a personal medical consultation.

Written by Dr. Marcus Rivera, MD, Endocrinology

Hormone Therapy Specialist. This article was researched against primary regulatory, trial, prescribing, and manufacturer sources where available. Reviewed by Dr. David Kim, MD, FACE for medical accuracy, sourcing, and patient-safety framing.

Ready to get started?

Provider-reviewed GLP-1 and peptide therapy, delivered to your door.

Start Your Consultation

Ready to Start Your Weight Loss Journey?

Get a free medical consultation with a licensed provider. Compounded GLP-1 medications starting at $99/month with free shipping.

Next Best Reads

Free Tools

Provider-informed calculators to support your weight loss journey.